Who are Bone Marrow Aspirate Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Platelet Rich Plasma (PRP), hUCB, Cord Blood Cell, Cytokine-induced killer cells+ FOLFOX4, umbilical cord-mesenchymal stem cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bone-marrow-aspirate-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bone Marrow Aspirate Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Marrow Aspirate Injection (Bone Marrow Aspirate Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine.

phase 3 Cell therapy Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Bone Marrow Aspirate Injection (Bone Marrow Aspirate Injection) — Federal University of São Paulo. Bone marrow aspirate injection delivers autologous bone marrow-derived cells to promote tissue regeneration and repair through paracrine signaling and stem cell differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bone Marrow Aspirate Injection TARGET	Bone Marrow Aspirate Injection	Federal University of São Paulo	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy
Cytokine-induced killer cells+ FOLFOX4	Cytokine-induced killer cells+ FOLFOX4	China Meitan General Hospital	marketed	Cell therapy combined with chemotherapy
umbilical cord-mesenchymal stem cells	umbilical cord-mesenchymal stem cells	General Hospital of Shenyang Military Region	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bone Marrow Aspirate Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bone-marrow-aspirate-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing